Abstract
The contribution of neurohormonal abnormalities in the pathophysiology of chronic heart failure (CHF) is well established. Attenuation of the excessive and continuous activation of angiotensin II and β-adrenergic receptors in patients with CHF with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, respectively, has resulted in substantial reductions in morbidity and mortality. However, it is not clear whether intervention with other neuroendocrine modulators (e.g., tumor necrosis factor [TNF] or endothelin) could result in similar benefits.
Original language | English (US) |
---|---|
Title of host publication | Acute Heart Failure |
Publisher | Springer London |
Pages | 621-625 |
Number of pages | 5 |
ISBN (Print) | 9781846287817 |
DOIs | |
State | Published - 2008 |
ASJC Scopus subject areas
- General Medicine